NAPSR News: FDA approves new acne scar treatment

By:
 
WASHINGTON - Jan. 7, 2015 - PRLog -- The U.S. Food and Drug Administration has approved Suneva Medical’s dermal filler Bellafill® to treat acne scars. Bellafill® is the first filler to be approved on the market to treat scars left by acne which is the most common skin disorder in the U.S, affecting up to 40-50 million people. According to an independent study approximately 70% of individuals reported that acne scars have severely impacted their self-confidence and self esteem and 92% indicated a treatment option for these scars would be a great improvement to their appearance and confidence level.  Bellafill® works by adding volume and smoothing out pitted acne scars to the level of surrounding skin.

These types of acne scars affect millions of people and can have a profoundly negative impact on their self-esteem and self-confidence," said Nicholas L. Teti, Jr., Chairman and Chief Executive Officer at Suneva Medical. "The results of this rigorous clinical study prove that Bellafill® reduces the appearance of acne scars—providing a solution to this widespread skin condition that previously had limited treatment choices. Bellafill® can have a transformational effect on a patient's appearance and in turn, we hope an improvement in quality of life."

Regulatory approval of Bellafill® stems from a double double-blinded, randomized, placebo-controlled pivotal study. Bellafill® demonstrated a superior response rate as 64% of the subjects studied showed improvement at a 6 month interval compared to 33% of individuals treated with a Control saline injection as defined by the 4-point Acne Scar Rating Scale (ASRS). To assess secondary effective endpoints, appearance was also evaluated on the Global Aesthetic Improvement Scale that was blinded through 6 months and unblinded at 12 months. On the Physician Global Aesthetic Improvement Scale (PGAIS) 84% showed improvement at 6 months and 98% at 12 months by an unblinded assessment. On the Subject Global Aesthetic Improvement Scale (SGAIS), 77% had an improved appearance at 6 months and 83% had improvement at 12 months. At 6 months (blinded) 84% were satisfied with their appearance while 90% were satisfied at 12 months (unblinded) as rated on the Subject Assessment of Scar Correction scale (SASC).

With such industry leaders paving the way on identifying new beneficial therapeutic breakthroughs, they will need both certified and qualified individuals to promote their diversified product portfolio. When industry leaders look for new candidates for sales/marketing positions, they look toward individuals that are industry trained. Companies are looking for people that have the background to promote their product both proficiently and efficiently.

The NAPSRx® is a trade association for pharmaceutical sales reps, sales managers and sales trainers who work in the pharmaceutical industry. NAPSRx® provides Continuing Medical Education to its members as well as CNPR® Certification to candidates who look to enter a pharmaceutical sales career. The CNPR® Program represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Upon successful completion of the training each student will receive the Certification Mark of the CNPR®.

Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives(NAPSRx) for more information or visit the website at http://napsronline.org/.

Contact
NAPSRx
***@napsronline.org
1-800-284-1060
End
Source: » Follow
Email:***@napsronline.org Email Verified
Tags:Napsrx, Napsr, CNPR Certification Program, Pharmaceutical Sales
Industry:Biotech, Health
Location:Washington - District of Columbia - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
NAPSRx PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share